DUBLIN--(BUSINESS WIRE)--Alkermes plc (NASDAQ: ALKS) today announced positive topline results from a phase 1 study of its new antipsychotic candidate, ALKS 3831, a combination of a proprietary drug molecule, ALKS 33, and olanzapine, a molecule that is commercially available under the name ZYPREXA®. ALKS 3831 is in development for the treatment of schizophrenia, a central nervous system (CNS) disease, and is designed to attenuate the antipsychotic-related metabolic side effect of weight gain.
